article thumbnail

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Cardiovascular Diabetology

Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Results Among all patients (n = 38,671), 31% had stable CAD, and 69% suffered an acute myocardial infarction. vs. 6.8%), myocardial infarction (7.7%

article thumbnail

Surgical repair of left ventricular free-wall rupture complicating acute myocardial infarction: a single-center 30 years of experience

Frontiers in Cardiovascular Medicine

Background Left ventricular free-wall rupture (LVFWR) is a catastrophic complication of acute myocardial infarction (AMI). However, because of the rarity of this entity, little is known regarding the efficacy and safety of surgical treatment for post-infarction LVFWR.

article thumbnail

In‐Hospital Outcomes in Patients With Acute Myocardial Infarction and No Standard Modifiable Cardiovascular Risk Factors Across Varying Body Mass Index: Findings From the CCC‐ACS Project

Journal of the American Heart Association

Multivariable logistic regression models were used to estimate BMIstratified associations between SMuRFless status and outcomes.ResultsThe study included 44 538 patients with firstpresentation acute myocardial infarction, of whom 4454 were SMuRFless. Journal of the American Heart Association, Ahead of Print.

article thumbnail

Role of lymphocyte-to-C-reactive protein ratio in forecasting microvascular obstruction in ST-segment elevation myocardial infarction post-percutaneous coronary intervention

Frontiers in Cardiovascular Medicine

BackgroundCurrent research suggests that microvascular obstruction (MVO) following the first percutaneous coronary intervention (PCI) in myocardial infarction patients is closely related to inflammatory responses. However, the relationship between LCR and MVO remains unclear.

article thumbnail

Early versus delayed complete revascularisation in patients presenting with ST-segment elevation myocardial infarction and multivessel disease: a systematic review and meta-analysis of randomised controlled trials

Open Heart

Background Several studies have demonstrated that complete revascularisation improves clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease. However, the optimal timing of non-culprit lesion revascularisation remains controversial.

article thumbnail

Atherothrombotic Outcomes After Sodium‐Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes: A Territory‐Wide Retrospective Cohort Study

Journal of the American Heart Association

The primary outcome was atherothrombotic major adverse cardiovascular events as a composite outcome of cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction. Patients were propensity matched in a 1:1 ratio using a caliper distance of 0.2 without replacement.

article thumbnail

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial

Circulation

Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Circulation, Ahead of Print. mg·kg·h of bivalirudin intravenously). mg·kg·h of bivalirudin intravenously). to 1.57]).